BAYN - ADC Therapeutics Begins U.S. IPO Process
Quick Take
ADC Therapeutics (ADCT) has filed to raise gross proceeds of up to $150 million from a U.S. IPO, according to an F-1 registration statement.
The firm is developing targeted antibody drug conjugates [ADCs] for the treatment of hematological malignancies and solid tumors.
ADCT has achieved very promising patient response rates with its lead candidate. I’ll provide an update when we learn more IPO details from management.
Company & Technology
Epalinges, Switzerland-based ADC was founded in 2011 as a Spirogen (LON:AZN) spin-off to develop ADC-based therapeutics for patients suffering